Clinical Trial Results:
A Phase 4, Multicenter, Open-Label Safety Study of Crisaborole Ointment 2% in Children Aged 3 Months to Less Than 24 Months Wth Mild to Moderate Atopic Dermatitis (AD)
Summary
|
|
EudraCT number |
2019-002836-10 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
12 Apr 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Oct 2019
|
First version publication date |
04 Oct 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
C3291002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03356977 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pfizer, Inc.
|
||
Sponsor organisation address |
235 E 42nd Street, New York, United States, NY 10017
|
||
Public contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Scientific contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
26 Apr 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Apr 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To study the safety of crisaborole ointment 2% applied twice daily (BID) in children aged 3 months
to less than 24 months with mild to moderate AD
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and
in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP)
Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Jan 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 15
|
||
Country: Number of subjects enrolled |
Canada: 10
|
||
Country: Number of subjects enrolled |
United States: 112
|
||
Worldwide total number of subjects |
137
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
137
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
- | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
The study was conducted in the 3 countries from 16 January 2018 to 12 April 2019. A total of 137 subjects were enrolled. | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
Crisaborole Topical Ointment, 2 Percent | ||||||||||||
Arm description |
Subjects with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent on treatable AD lesions, twice daily from Day 1 to Day 29. Treatable AD lesions were identified at Baseline (Day 1) by investigator. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Crisaborole Topical Ointment, 2%
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Ointment
|
||||||||||||
Routes of administration |
Topical use
|
||||||||||||
Dosage and administration details |
Crisaborole topical ointment, 2 percent to treatment targeted lesions, twice daily from Day 1 to Day 29.
|
||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Crisaborole Topical Ointment, 2 Percent
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent on treatable AD lesions, twice daily from Day 1 to Day 29. Treatable AD lesions were identified at Baseline (Day 1) by investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Crisaborole Topical Ointment, 2 Percent
|
||
Reporting group description |
Subjects with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent on treatable AD lesions, twice daily from Day 1 to Day 29. Treatable AD lesions were identified at Baseline (Day 1) by investigator. |
|
|||||||||||||
End point title |
Number of Subjects With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions [1] | ||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Site reactions are reactions which occurred in subjects at the site of application of investigational product. Safety analysis set included any subject who received at least 1 dose of investigational product.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline (Day 1) up to at least 28 days after last dose of investigational product (up to 60 days)
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects With Clinically Significant Height Values Meeting Pre-defined Criteria [2] | ||||||||||
End point description |
Height of subjects was measured in terms of centimeter (cm). The pre-defined criteria for measuring the height was less than (<) 55 cm and greater than (>) 92.5 cm. Safety analysis set included any subject who received at least 1 dose of investigational product. . Here, “Number of Subjects Analysed" signifies subjects who were evaluable for this endpoint.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects With Clinically Significant Weight Values Meeting Pre-defined Criteria [3] | ||||||||||
End point description |
Weight of subjects was measured in terms of kilogram (kg). The pre-defined criteria of measuring the weight of subjects was less than equal to (<=) 4.5 kg and >15 kg. Safety analysis set included any subject who received at least 1 dose of investigational product. Here, "Number of Subjects Analysed" signifies subjects who were evaluable for this endpoint.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Number of Subjects With Clinically Significant Blood Pressure Values Meeting Pre-defined Criteria [4] | ||||||||||||||
End point description |
Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) of subjects was measured in terms of millimeters of mercury (mmHg). The clinically significant pre-defined criteria were, SBP: change of greater than equal to (>=) 30 mmHg increase from baseline (IFB) and SBP change of >= 30 mmHg decrease from baseline (DFB); DBP: change of >=20 mmHg IFB and DBP change of >=20 mmHg DFB. Safety analysis set included any subject who received at least 1 dose of investigational product. Here, "Number of Subjects Analysed" signifies subjects who were evaluable for this endpoint and "n" signifies subjects evaluable for specific rows.
|
||||||||||||||
End point type |
Primary
|
||||||||||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects With Clinically Significant Pulse Rate Values Meeting Pre-defined Criteria [5] | ||||||||||
End point description |
Pulse rate of subjects was measured in terms of beats per minute (bpm). The pre-defined criteria of measuring the pulse rate of subjects was <90 bpm and >180 bpm. Safety analysis set included any subject who received at least 1 dose of investigational product.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects With Clinically Significant Respiratory Rate Values Meeting Pre-defined Criteria [6] | ||||||||||
End point description |
Respiratory rate was measured in terms of number of breaths per minute. The pre-defined criteria of measuring the respiratory rate of subjects was < 22 breaths per min and > 53 breaths per min. Safety analysis set included any subject who received at least 1 dose of investigational product.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Baseline (Day 1), Day 8, Day 15, Day 29 (end of treatment)
|
||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Subjects With Clinically Significant Body Temperature Values Meeting Pre-defined Criteria [7] | ||||||
End point description |
Body temperature of subjects was measured in degree Celsius. The normal body temperature value was >= 39 degree Celsius. Safety analysis set included any subject received at least 1 dose of investigational product.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Subjects With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values Meeting Pre-defined Criteria [8] | ||||||||||||||||
End point description |
ECG of subjects was measured in terms of millisecond (msec). ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Fridericia's formula (QTcF). ECG values meeting pre-defined criteria were 1) PR interval: greater than equal to (>=) 25 percent (%) increase when baseline greater than (>)200 milliseconds (msec); or increase >=50% when baseline less than or equal to (<=200) msec; 2) QRS interval: >=25% increase when baseline >100 msec; >=50% increase when baseline <= 100 msec; 3) QTCF interval: QTc interval using Fridericia’s formula (QTcF interval) > 30 msec. IFB stands for increase from baseline. Safety analysis set included any subject who received at least 1 dose of investigational product. Here, “Number of Subjects Analysed" signifies subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||||||||||||
Notes [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Subjects With Clinically Significant Laboratory Parameters Meeting Pre-defined Criteria [9] | ||||||
End point description |
Criteria: hematology: hemoglobin, hematocrit, erythrocytes < 0.8*lower limit of normal (LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN), leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, bicarbonate <0.9* LLN >1.1* ULN, glucose <0.6*LLN >1.5*ULN. Safety analysis set included any subject who received >=1 dose of investigational product. Here, "Number of Subjects Analysed" signifies subjects who were evaluable for this endpoint.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
Baseline (Day 1) up to Day 29 (end of treatment)
|
||||||
Notes [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analyzed for this endpoint. |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline (Day 1) up to at least 28 days after last dose of investigational product (up to 60 days)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as non-serious in another, or a subject may have experienced both a serious and non-serious event.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Crisaborole Topical Ointment, 2 Percent
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with mild to moderate AD received crisaborole ointment, 2 percent on treatable AD lesions, twice daily from Day 1 to Day 29. Treatable AD lesions were identified at Baseline (Day 1) by investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 May 2018 |
Added that any subject with a new or ongoing adverse event at the time of the Day 57 (end of study) follow-up contact, should be seen in the clinic for evaluation of that adverse event. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |